Innovation within reach.

Investing in PAVmed is investing in innovation that has the potential to impact and even transform healthcare. Stay informed about the latest news and updates from our team.



PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform. Its other majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths.

Stock Information
Market Cap
Stock Information

Latest News & Updates

Dec 4, 2023

PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on

Nov 16, 2023

Industry veterans join executive team as VP, Market Access and VP, Employer Markets Shaun M. O'Neil promoted to Lucid's President and COO NEW YORK, Nov. 16, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.

Nov 14, 2023

Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and...



Get in touch.

Interested in collaborating or looking for more information about our innovations, events, products or partnerships? Connect with us.


Investor Updates

Email Alerts

Sign up for our investor mailing list below to receive the latest news and financials form PAVmed delivered to your inbox.